APOB Antibody [D10H9] | 14-891

APOB Antibody [D10H9] | 14-891 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human

Homology: N/A

Immunogen: Recombinant protein of human APOB

Research Area: Cancer, Signal Transduction

Tested Application: WB, ICC, Flow

Application: WB: 1:500 - 1:2000
ICC: 1:500 - 1:1000
Flow: 1:50 - 1:200

Specificiy: N/A

Positive Control 1: Recombinant protein

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: Observed: 45kDa

Validation: N/A

Isoform: N/A

Purification: Affinity purification

Clonality: Monoclonal

Clone: [D10H9]

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

Concentration: N/A

Storage Condition: Store at -20˚C. Avoid freeze / thaw cycles.

Alternate Name: APOB, apolipoprotein B (including Ag (x) antigen) , FLDB, apoB-100, apoB-48, apolipoprotein B, apolipoprotein B48, LDLCQ4

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: This gene product is the main apolipoprotein of chylomicrons and low density lipoproteins. It occurs in plasma as two main isoforms, apoB-48 and apoB-100: the former is synthesized exclusively in the gut and the latter in the liver. The intestinal and the hepatic forms of apoB are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA->UAA) , resulting in the creation of a stop codon, and early translation termination. Mutations in this gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective apoB, diseases affecting plasma cholesterol and apoB levels.